For the last 10 years, improving R&D productivity has been one of the key challenges of pharmaceuticals companies. Streamlining management of R&D projects, forming alliances, building long-term agreements with academic or biotech research teams, licensing-in phase II-III projects with sophisticated deal structures have been typical and sometimes very effective solutions.
However, none of these approaches have really addressed the central problem of pharmaceutical R&D today. To find new drugs tomorrow, scientists will need to better understand the molecular processes that govern diseases, and how genetic diversity of patients influences treatment outcomes.
In parallel, the industrialization of molecular biology techniques has led to significant progress in the detection and analysis of increasingly complex molecules. Those include long DNA/RNA fragments, proteins, or even entire cells. These techniques have allowed scientists to gain a much more accurate understanding of the molecular processes which are at the origin of many diseases. Their potential is immense, not only in R&D, but also in daily medical practice.
Today, more than half of new drugs is originated from biotechnology research, and the proportion is increasing rapidly. Biotechnology has become an established component in the drug innovation value chain. Despite recent downturns on the capital markets that have impacted the biotechnology sector, the overall growth of biotechnology within the past five years has been nothing less than spectacular.
Major pharmaceuticals companies are turning their attention more and more to acquiring new biotechnological targets. stradoo® creates additional value for its clients by supporting them in screening the target landscape quickly, assessing target values and providing transaction solutions. Those reach from strategy definition to M&A execution.